A Double Blind, Polysomnographic, Three-Way Crossover Study to Compare the Efficacy of Two Doses of Gastric Retentive Dual Release Zaleplon (Zaleplon AP) to Placebo in Subjects With Insomnia Characterized by Both Difficulty in Falling Asleep and Staying Asleep.

Trial Profile

A Double Blind, Polysomnographic, Three-Way Crossover Study to Compare the Efficacy of Two Doses of Gastric Retentive Dual Release Zaleplon (Zaleplon AP) to Placebo in Subjects With Insomnia Characterized by Both Difficulty in Falling Asleep and Staying Asleep.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Zaleplon (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Intec Pharma
  • Most Recent Events

    • 01 Aug 2012 Actual end date (1 Sep 2011) added as reported by ClinicalTrials.gov.
    • 22 Nov 2011 Primary endpoint 'Wake-time-after-sleep-onset' has been met, according to an Intec Pharma media release.
    • 22 Nov 2011 Primary endpoint 'Polysomnographic-measures' has been met, according to an Intec Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top